"Neoadjuvant therapy and axillary lymph node status in HER2-positive breast cancer".
Sabine DanzingerChristian PfeiferSophia WimmerKristina Tendl-SchulzChristian F SingerPublished in: Cancer investigation (2023)
Based on an estimating model, the aim of our study was to evaluate the axillary lymph node involvement of patients with primary invasive early human epidermal growth factor receptor 2 (HER2)-positive breast cancer before receiving neoadjuvant therapy (NAT). Patients with primary surgery (n = 63) were compared with patients who had received NAT (combined chemo/HER2-targeted antibody therapy) before surgery (n = 152). In patients receiving NAT, a positive N stage was estimated in 73.2 (49.8%) tumors resulting in a conversion (positive N stage-ypNpositive) of 35.5%. In 126 cases with ypN0 stage, a positive N stage was estimated in 41.4%.
Keyphrases
- lymph node
- positive breast cancer
- epidermal growth factor receptor
- sentinel lymph node
- neoadjuvant chemotherapy
- minimally invasive
- coronary artery bypass
- endothelial cells
- rectal cancer
- cancer therapy
- stem cells
- cell therapy
- radiation therapy
- photodynamic therapy
- surgical site infection
- early stage
- atrial fibrillation
- induced pluripotent stem cells